The U.S. Patent & Trademark Office rules in favor of C.R. Bard in a long-running lawsuit accusing W.L. Gore of infringing on stent-graft technology.
C.R. Bard (NYSE:BCR) today announced that it won a favorable ruling from the U.S. Patent & Trademark Office, which notified the medical device maker that it intends to uphold the patentability of the stent-graft patent at the heart of a long-running infringement lawsuit with W.L. Gore & Assoc.
The USPTO announcement won some favor from Wall Street analysts and was followed by a 0.8% increase in BCR shares, which were trading at $110.31 as of about 1:35 p.m. today. Morgan Stanley analyst David Lewis today reiterated an "underweight" rating on Bard in light of the ruling.